Doctrine Of Equivalents Cannot Eliminate Claim Element
Client Alert | 1 min read | 12.19.06
In Planet Bingo, LLC v. Gametech Int'l, Inc. (No. 05-1476; December 13, 2006), the Federal Circuit affirms a decision of the district court in which defendant was found not to infringe Planet Bingo's patents directed to alternative methods for playing bingo. The district court held that the claim language “establishing a predetermined combination as a winning combination for a progressive jackpot” required that the winning combination must be established before the bingo game begins. As defendant's game did not disclose to a player what the winning combination was until after the game began, the district court found no literal infringement. In addition, the district court rejected plaintiff's assertions of infringement under the doctrine of equivalents, as interpreting “after” to include “before” would eliminate the requirement that the winning combination be “predetermined.” On appeal, the Federal Circuit states that it “cannot overlook [a] limitation or expand the doctrine of equivalents beyond its purpose to allow recapture of subject matter excluded by a deliberate and foreseeable claim drafting decision,” and, therefore, affirms the district court's decision.
Insights
Client Alert | 8 min read | 06.30.25
AI Companies Prevail in Path-Breaking Decisions on Fair Use
Last week, artificial intelligence companies won two significant copyright infringement lawsuits brought by copyright holders, marking an important milestone in the development of the law around AI. These decisions – Bartz v. Anthropic and Kadrey v. Meta (decided on June 23 and 25, 2025, respectively), along with a February 2025 decision in Thomson Reuters v. ROSS Intelligence – suggest that AI companies have plausible defenses to the intellectual property claims that have dogged them since generative AI technologies became widely available several years ago. Whether AI companies can, in all cases, successfully assert that their use of copyrighted content is “fair” will depend on their circumstances and further development of the law by the courts and Congress.
Client Alert | 3 min read | 06.30.25
Client Alert | 3 min read | 06.26.25
FDA Targets Gene Editing Clinical Trials in China and other “Hostile Countries”
Client Alert | 3 min read | 06.26.25